AbClon specializes in developing antibody-based new drugs for intractable diseases. The company's technology includes platform technologies such as NEST, AffiMab, and CAR-T, which allow for extensive pipeline scalability. Unlike other biotech companies, it has a process capable of continuously deriving new antibody drug candidates based on its innovative antibody discovery platform.

AbClon’s proprietary zCAR-T treatment is the next generation of CAR-T treatment whose modularity can allows its to be used against various cancer targets as well modulating the activity of CAR-T cells within the patient. NEST (Novel Epitope Screening Technology) is a discovery platform for antibody treatments that bind to a unique site (epitope) of a disease protein, and shows a contrasting effect compared to existing antibody treatments. These unique antibodies developed through NEST also have shown strong synergy effect when used in combination with existing, commercialized antibody treatments. AffiMab combines the advantages of monoclonal antibodies and Affibody technology. The platform allows for engineering a bispecific antibody with affinity for two different target proteins. Bispecific antibodies demonstrate superior therapeutic effect compared to monoclonal antibody treatments in refractory diseases. Furthermore, AffiMab demonstrates high molecular stability in vivo and excellent production yields.

Public

Biotech